What's new?

• Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe.
• With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies.
• Bpifrance* and CNP Assurances acted as sponsors for the fund.

Paris, France – April 4th, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today the launch of Sofinnova Crossover I with €275 million ($340 million), above the original first close target of €250 million. With this new fund, Sofinnova Partners goes one step further in the execution of its growth plan, aimed at expanding its coverage across the Life Sciences space with dedicated sector teams.

Pursuing a strategy Sofinnova Partners has successfully applied for decades with its early-stage focused Capital Funds, Sofinnova Crossover I will invest in the biopharmaceutical and medical device sectors. The fund will focus primarily on therapeutic and game-changing companies driven by experienced management. As a lead or cornerstone investor, the fund will seek to invest in about 15 late stage private and public companies. About 80% of the investments will be made in European companies, with the remaining 20% outside of Europe primarily in North America. A dedicated, highly experienced team of four partners will invest Sofinnova Crossover I, leveraging on Sofinnova Partners’ wider experience, track record and organizational support. This new fund attracted premier international investors, predominantly sovereign funds, insurance companies, corporations and family offices. Commitments came from Europe, including France, Italy, Denmark, Ireland, and Switzerland but also from Asian investors in China and Singapore. In addition to Bpifrance* and CNP Assurances, investors include a major Chinese biopharmaceutical company, the Danish State Investment fund, and family offices like Fidim or KCK representing leading industrial families in Europe and Asia.

Antoine Papiernik, Chairman of Sofinnova Partners, said, “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the years large, billion-euro companies, and we have gained invaluable experience in helping them to the next level. This fund will complete our investment platform across the life-sciences value-chain, allowing us to fund companies from the seed stage to the late-stage.”

Jacques Theurillat, Partner in the crossover team at Sofinnova Partners, added: “The European healthcare market has matured with hundreds of late stage private and public companies looking for growth capital, and Sofinnova Partners, with its name, track record and experience, is particularly well positioned to identify the best European deals and transform them into global leaders.”

Triago acted as placement agent and Clifford Chance Europe LLP acted as legal counsel on Sofinnova Crossover I.

* Bpifrance directly and with the “Investment for the Future” Program, managed by the SGPI and operated by Bpifrance

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management.


October 23, 2003 Seattle, Washington and Milan, Italy—Cell Therapeutics, Inc.
(CTI) (NASDAQ: CTIC) and Novuspharma S.p.A. (Novuspharma) (Nuovo Mercato: NOV.MI
and NOV IM) today announced that the shareholders of both companies have
approved the merger of Novuspharma with and into CTI. The transaction, which was
first announced on June 17, 2003, is expected to close late in the fourth
quarter of 2003 or early in the first quarter of 2004. As consideration for the
transaction, CTI will issue approximately 16 million shares of its common stock,
based on the number of Novuspharma ordinary shares outstanding as of June 16,
2003. Following the merger, the combined company will have one marketed product,
its own sales force and a pipeline of anti-cancer drugs. The merger is expected
to strengthen the balance sheet of the combined entity, with approximately 5
million in cash, cash equivalents and securities available-for-sale (pro-forma
at Sept. 30, 2003), and a projected -20 million a year in cost savings starting
in 2004. About Novuspharma S.p.A. Novuspharma S.p.A. is a biopharmaceutical
company that leverages its expertise in the field of oncology to discover and
develop innovative new treatments for cancer. The Company is traded on the Nuovo
Mercato of the Borsa Italiana. Based in Bresso (Milan), Italy, Novuspharma began
operations in 1999, following its spin-off from Boehringer Mannheim and
Hoffmann-La Roche. The company was spun-out in order to exploit the research and
development team’s expertise in the field of cancer research. The Company has a
broad and diverse product portfolio and a rich research pipeline including new
generations of existing therapies and completely novel classes of pharmaceutical
agents. For additional information, please visit http://www.novuspharma.com/.
Cell Therapeutics, Inc. Based in Seattle, Washington, CTI is a biopharmaceutical
company committed to developing an integrated portfolio of oncology products
aimed at making cancer more treatable. For additional information, please visit
This press release contains
forward-looking statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These statements are based
on management’s current expectations and beliefs and are subject to a number of
factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The forward-looking
statements contained in this press release include statements about future
financial and operating results and the proposed CTI/Novuspharma merger. These
statements are not guarantees of future performance, involve certain risks,
uncertainties and assumptions that are difficult to predict, and are based upon
assumptions as to future events that may not prove accurate. Therefore, actual
outcomes and results may differ materially from what is expressed herein. For
example, if either of the companies fails to satisfy conditions to closing, the
transaction will not be consummated. In any forward-looking statement in which
CTI expresses an expectation or belief as to future results, such expectation or
belief is expressed in good faith and believed to have a reasonable basis, but
there can be no assurance that the statement or expectation or belief will
result or be achieved or accomplished. The following factors, among others,
could cause actual results to differ materially from those described in the
forward-looking statements: the risk that the CTI and Novuspharma businesses
will not be integrated successfully; costs related to the proposed merger; and
other economic, business, competitive, and/or regulatory factors affecting CTI’s
and Novuspharma’s businesses generally, including those set forth in CTI’s
filings with the SEC, including its Annual Report on Form 10-K/A for its most
recent fiscal year and its most recent Quarterly Report on Form 10-Q, especially
in the “Factors Affecting Our Operating Results” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” sections, and its
Current Reports on Form 8-K and Registration Statements on Forms S-3 and S-4.
CTI is under no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements whether as a result of new
information, future events, or otherwise.
Visit website http://www.novuspharma.com


FOR IMMEDIATE RELEASE: Ingenium Appoints Dr. Klaus Dembowsky to Vice President Drug Discovery

Munich, Germany, September 2, 2003 -Ingenium Pharmaceuticals AG announced today that Klaus Dembowsky, M. D., Ph. D., has joined the company as Vice President Drug Discovery and will lead research and development activities, focusing on advancing Ingenium’s internal drug discovery portfolio toward clinical testing. Dr. Dembowsky joins Ingenium from Bayer Corporation, where he spent over 10 years in drug discovery and development, most recently as a manager of the Bayer-Millennium collaboration for drug target discovery. “Klaus brings to us the right mix of pharmaceutical development expertise, hands-on discovery and collaboration experience and valuable research focus in both the drug classes and therapeutic areas of primary importance,” commented Michael C. Nehls, M. D., Ph. D., Chief Executive Officer of Ingenium. “At this critical juncture in Ingenium’s development as a drug discovery leader, we are thrilled to have Klaus work with us to build our internal strength and lead our research and development.”

Dr. Dembowsky has over 20 years experience in pharmaceutical research and development and academic research. Over the course of his 10-year tenure at Bayer Corporation, Dr. Dembowsky was active across all stages of drug discovery and development, including drug target identification and selection, compound optimization, pre-clinical drug development and clinical trial consultation. Most recently, Dr. Dembowsky was Project Manager and Team Leader for the Bayer- Millennium target discovery collaboration on site at Millennium’s facilities in Cambridge/ MA. Prior to Bayer, Dr. Dembowsky was Associate Professor of Physiology at the University of Heidelberg. Dr. Dembowsky has conducted extensive academic research in the area of neurobiology and has co-edited a book on recombinant proteins. Dr. Dembowsky received his Ph. D. in physiology and his M. D. from the University of Heidelberg.

Ingenium Pharmaceuticals bases its business on generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium’s technologies are based on a unique functional analysis of the mammalian genome at the organism level. Using its Deductive Genomics™ approach, Ingenium has produced a portfolio of medically relevant novel biological discoveries in the areas of inflammatory bowel disease, diabetes/ obesity, and neurobiology. In addition, the company had developed complimentary biomedical discovery and validation platforms (INGENOtyping™ and INGENOtypes®), which it uses internally and provides to its partners. To date, Ingenium’s partners include Elan Corporation, F. Hoffmann-La Roche Ltd., Sequenom Inc., Oxagen Ltd and multiple academic institutions.

Visit website http://www.ingenium-pharma.com


Servista is enabling Lloyds TSB to become the first UK bank to offer an integrated gas, electricity and telephone service to its customers. The new service, to be branded ‘Ideal from Lloyds TSB’, will be made possible by Servista’s unique managed service offering and underlying technology platform.

As the UK’s leading provider of business process outsourcing (BPO) for the emerging ‘home services’ market, Servista helps companies to unlock more value from their consumer brands by enabling them to enter new markets in a rapid, low risk manner. Servista, in conjunction with its partners, provides a complete ‘turn-key’ solution that allows multiple services to be offered and managed via one solution. Servista manages the customer journey from registration to billing to collection, and includes customer relationship management (CRM) and marketing analytics capabilities. Servista’s clients are thus able to focus on marketing new services whilst outsourcing customer management to Servista.

Courtney Sheets, CEO of Servista commented: “The deregulation of the utilities markets in the UK has opened up many opportunities for consumer brands to deliver a new proposition to their customer base, and it is exciting to see Lloyds TSB make that move today. We are delighted that Lloyds TSB selected Servista to be their expert partner in the home services market.”

Darryn Melrose, Head of Non Financial Services for Lloyds TSB’ commented: “When we started to develop our proposition, we went straight to Servista; they have unrivalled knowledge and experience in home services. We have been working with Servista for some time now in order to ensure that our service is at the very leading edge in terms of quality, convenience and value. I have been impressed by the innovation that they have brought to our offering, and I am very confident that they will enable Lloyds TSB to deliver extra-ordinary service to our customers”.

For further information, please contact
Scott Sunderman, Servista
phone: +44 (0) 20 7813 5114
email: scott.sunderman@servista.com.

Tom Buchanan/Fiona Fong, Brunswick
phone: +44 (0) 20 7404 5959
email: servista@brunswickgroup.com.

Visit website http://www.servista.com